Relative Impact of Pain and Disease Activity on Improvements in Fatigue - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue JCR: Journal of Clinical Rheumatology Année : 2022

Relative Impact of Pain and Disease Activity on Improvements in Fatigue

Résumé

Background/Objective: Fatigue is common in patients with rheuma-toid arthritis (RA). We assessed the relative impact of pain and disease activity on improvements in fatigue in 2 phase 3 baricitinib clinical trials. Methods: RA-BEAM (NCT01710358) and RA-BEACON (NCT01721044) were randomized, double-blind, placebo-controlled studies in adults with moderate to severe RA. RA-BEAM assessed baricitinib + methotrexate (MTX) and adalimumab + MTX in patients with prior inadequate response/intolerance (IR) to MTX (MTX-IR). RA-BEACON assessed patients with IR to ≥1 biologic disease-modifying antirheumatic drug (bDMARD-IR). Measures included the Functional Assessment of Chronic Illness Therapy-Fatigue scale, Clinical Disease Activity Index (CDAI) for RA, and pain visual analog scale (VAS). Analyses were implemented separately for each study. Results: Significant improvements were seen in disease activity and pain, which were greater with baricitinib versus adalimumab. A statistically significant improvement was seen in fatigue with both active treatments versus placebo. Moderate correlations were observed between improvements in disease activity and fatigue and between improvements in pain and fatigue in both MTX-IR and bDMARD-IR patients. Reductions in pain (≥50%) and remission or low disease activity (CDAI ≤10) had significant associations with fatigue improvement at week 24. In mediation analysis, improvements in fatigue attributable to CDAI and pain VAS in MTX-IR patients were 31% and 52%, respectively, for baricitinib, and 30% and 47%, respectively, for adalimumab. In bDMARD-IR patients, improvement in fatigue was attributed 48% to CDAI and 48% to pain VAS. Conclusions: In both MTX-IR and bDMARD-IR patients, a large proportion of improvements in fatigue across treatment arms were accounted for by improvements in pain and disease activity.
Fichier principal
Vignette du fichier
3105.pdf (443.08 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03986742 , version 1 (24-02-2023)

Identifiants

Citer

Bruno Fautrel, Jianmin Wu, Duzhe Wang, Ewa Haladyj, Mart a F J van de Laar, et al.. Relative Impact of Pain and Disease Activity on Improvements in Fatigue. JCR: Journal of Clinical Rheumatology, 2022, PublishAheadofPrint, ⟨10.1097/rhu.0000000000001924⟩. ⟨hal-03986742⟩
3 Consultations
10 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More